



CENTER FOR MEDICARE

DATE: November 28, 2022

TO: All Prescription Drug Plans, Medicare Advantage-Prescription Drug Plans, Section 1876 Cost Plans, Medicare-Medicaid Plans, and PACE Organizations

FROM: Amy Larrick Chavez-Valdez
Director, Medicare Drug Benefit and C & D Data Group

SUBJECT: Contract Year 2023 Part D Drug Management Program Guidance

This memorandum provides updated information to Part D sponsors regarding contract year (CY) 2023 Drug Management Programs (DMPs).

Following is a summary of changes compared to the September 30, 2021 memorandum, *Contract Year 2022 Part D Drug Management Program Guidance*. New and revised text in the attached guidance is shown in red, italicized font.

- Throughout: Edits made to clarify existing policy.
- Section 8.4: Added a new section that provides case examples highlighting requirements related to timing of beneficiary notices.
- Frequently Asked Questions (FAQs): The FAQs have been updated and will be posted as a separate document on the [CMS Part D Overutilization website](#).

Additional resources and guidance available on the [CMS Part D Overutilization website](#) include:

- Updated CY 2023 Overutilization Monitoring System (OMS) technical guidance.
- Links to final rules CMS-4182-F ([83 FR 16440](#)) and CMS-4190-F2 ([86 FR 5864](#)) codifying the initial framework for DMPs and 2022 program updates.
- Standardized beneficiary notices, model prescriber inquiry letter, and model transfer memo associated with PRA package CMS-10141 (OMB Control No. 0938-0964), which have been updated to reflect the most recent OMB approval through September 30, 2025.

The contents of this document do not have the force and effect of law and are not meant to bind the public in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law.

Further information about appeals of at-risk determinations can be found in the Parts C & D Enrollee Grievances, Organization/Coverage Determinations, and Appeals Guidance posted here:

<https://www.cms.gov/Medicare/Appeals-and-Grievances/MMCAG/Downloads/Parts-C-and-D-Enrollee-Grievances-Organization-Coverage-Determinations-and-Appeals-Guidance.pdf>

Questions about DMPs may be submitted to PartD_OM@cms.hhs.gov.